The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—Janssen’s Tremfya and AbbVie’s Rinvoq and Skyrizi. Furthermore…
Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first…
TNF-alpha inhibitors continue to be the preferred choice to treat psoriatic arthritis (PsA) following failure on conventional DMARDs. However, other biologics such as IL-17 inhibitors (e.g.,…
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics and/or…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key rheumatoid arthritis patient populations, covering 171 countries and…
Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…
Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…
Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…
Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…
Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…
Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…
DRG Epidemiology's coverage of rheumatoid arthritis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of rheumatoid…
Clarivate Epidemiology’s coverage of Sjogren’s syndrome (SS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of Sjogren’s syndrome (SS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
